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The significance of chromosome 3p gene alterations in lung cancer is poorly understood. This study set out to investigate promoter
methylation in the deleted in lung and oesophageal cancer 1 (DLEC1), MLH1 and other 3p genes in 239 non-small cell lung carcinomas
(NSCLC). DLEC1 was methylated in 38.7%, MLH1 in 35.7%, RARb in 51.7%, RASSF1A in 32.4% and BLU in 35.3% of tumours. Any two
of the gene alterations were associated with each other except RARb. DLEC1 methylation was an independent marker of poor
survival in the whole cohort (P¼0.025) and in squamous cell carcinoma (P¼0.041). MLH1 methylation was also prognostic,
particularly in large cell cancer (P¼0.006). Concordant methylation of DLEC1/MLH1 was the strongest independent indicator of
poor prognosis in the whole cohort (P¼0.009). However, microsatellite instability and loss of MLH1 expression was rare, suggesting
that MLH1 promoter methylation does not usually lead to gene silencing in lung cancer. This is the first study describing the
prognostic value of DLEC1 and MLH1 methylation in NSCLC. The concordant methylation is possibly a consequence of a long-range
epigenetic effect in this region of chromosome 3p, which has recently been described in other cancers.
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Lung cancer is one of the most common causes of cancer death.
The overall 5-year survival rate for surgical resection of stage I
non-small cell lung cancer (NSCLC) can achieve 60–75% while
survival rates in stage II–IV patients remain poor. Unfortunately
only a small subset responds to currently available treatments.
Thus, it is important to identify and characterise new molecular
markers and gene targets to improve the accuracy of prognosis and
develop more targeted treatment strategies to improve the clinical
management of lung cancer.
Allelic loss of chromosome 3p is one of the most frequent and
earliest documented events in lung cancer, with deletions at 3p24–
26, 3p21.3, 3p21.1–21.2, 3p14.2 and 3p12–13, suggesting the
presence of multiple tumour suppressor genes on 3p (Hung et al,
1995; Wistuba et al, 2000; Zabarovsky et al, 2002). Recent work has
revealed the involvement of frequent epigenetic alterations in the
inactivation of many 3p candidate genes, including BLU, FHIT,
RASSF1A, RARb and SEMA3B (Dammann et al, 2000; Virmani
et al, 2000; Zochbauer-Muller et al, 2001; Zabarovsky et al, 2002;
Ito et al, 2005). Detection of methylated genes in serum and
sputum DNA from lung cancer patients has also raised the
possibility of using DNA methylation as an early detection marker
(Esteller et al, 1999; Palmisano et al, 2000; Belinsky et al, 2002;
Usadel et al, 2002).
Methylation of the MLH1 gene in 3p22.3 and its correlation with
a mismatch repair defect and high microsatellite instability (MSI-
H) is well characterised in sporadic colorectal cancer, where this
phenotype is associated with better patient survival (Sinicrope
et al, 2006). In NSCLC MLH1 methylation has been described with
frequencies ranging from 7 to 59% (Yanagawa et al, 2003; Safar
et al, 2005) but in the absence of MSI-H (Benachenhou et al, 1998;
Okuda et al, 2005). LOH within the MLH1 gene has also been
detected in 55% (Benachenhou et al, 1998) and reduced MLH1
expression in 59% of lung cancers (Xinarianos et al, 2000). These
intriguing findings have been followed by a recent report that
MSH2, but not MLH1, methylation is a marker of poor prognosis
in a Taiwanese cohort of nonsmoking female NSCLC patients
(Hsu et al, 2005). It remains to be determined if a mismatch repair
gene defect has a role in lung carcinogenesis and why it is not
associated with typical MSI-H.
The deleted in lung and oesophageal cancer 1 (DLEC1) gene is
located about 1Mb centromeric from MLH1 (Figure 1A). The
3p21.3 region was identified as one of the common deleted regions
in lung cancer. Four candidate genes in this region were analysed
but no evidence of their involvement in cancer development was
found (Ishikawa et al, 1997). Further analysis led to the
identification of the DLC1 gene (Daigo et al, 1999), which was
later renamed DLEC1. Loss of DLEC1 expression has been
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sobserved in lung, oesophageal, renal, ovarian and nasopharyngeal
carcinoma cell lines and primary tumours and functional analyses
strongly suggest that DLEC1 is a tumour suppressor gene (Daigo
et al, 1999; Kwong et al, 2006, 2007). Promoter hypermethylation
has been shown to be responsible for silencing of DLEC1 in
ovarian cancer and in nasopharyngeal carcinoma (Kwong et al,
2006, 2007) but there has been no comprehensive methylation
analysis reported for lung cancer.
In this study, we investigated if promoter hypermethylation of
DLEC1 is found in lung cancer and whether it has any prognostic
significance. We determined the relationship of DLEC1 methyla-
tion with patient clinicopathologic variables and other 3p
molecular markers, in particular MLH1, RARb, RASSF1 and BLU
methylation.
PATIENTS AND METHODS
Lung cancer patients
We reviewed the NSCLC surgery database maintained by the one
cardiothoracic surgeon (BMC) for the period of 1994–2000.
Patients who had received induction chemotherapy or for whom
sufficient tissue was not available, were excluded. The final cohort
had 155 (64.9%) men and 84 women (35.1%) with a median age at
diagnosis of 68 years (range, 41–87 years) and a median survival
time of 36.9 months (range, 1–113 months). Data on survival was
obtained from the Cancer Registry of NSW, by routine follow-up
visits or contact with the patient’s general practitioner. Overall
survival was measured from the date of surgery to the date of death
or the date of last follow-up, censored patients being those who
were alive at the time of last follow-up.
This study cohort consisted of 92 (38.7%) adenocarcinomas
(ADC), 54 (22.7%) large cell carcinomas (LCC), and 92 (38.7%)
squamous cell carcinomas (SCC). These tumours were classified
according to the American Joint Committee on Cancer (AJCC)
tumour-node metastasis classification (Grondin and Liptay, 2002)
and consisted of 153 (64.0%) stage I and 86 (36.0%) stage II
tumours (Table 2). The study was approved by the Ethics
Review Committee of the Royal Prince Alfred Hospital (approval
no. X02-0216).
DNA extraction and bisulphite treatment
Hematoxylin and Eosin-stained sections from paraffin-embedded
tissue blocks were reviewed by an anatomical pathologist (WAC)
for tumour and matching normal tissue specimens. Six to twelve
serial 4mm sections of each block were used for DNA extraction,
depending on the size of the tissue. DNA extraction was carried out
using the Puregen Genomic DNA purification kit (Gentra Systems,
MN, USA). Sodium bisulphite conversion was performed as
previously described (Millar et al, 2002).
Expression of DLEC1 in lung cancer cell lines
Five lung cancer cell lines, A427, A549, NCI-H292, NCI-H1299 and
NCI-H358, were used. Total RNA and DNA were extracted from
cell pellets using RNeasy
s Mini Kit and DNeasy
s Tissue Kit
(Qiagen GmbH Inc., Germany), respectively. Normal human adult
lung RNA samples were purchased from Stratagene (Stratagene,
CA, USA). One microgram of RNA from each sample was used in a
reverse transcription reaction using GeneAmp RNA PCR kit
(Applied Biosystems, CA, USA). Expression of DLEC1 was assessed
by RT–PCR (DLEC1-F: 50-TTCCTCCCTCGCCTACTC-30;D L E C 1 - R :
50-AAACTCATCCAGCCGCTG-30). The primer pair was designed
across exons 1 and 2 of the main DLEC1 transcript NM_005106.
GAPDH was used as control.
To investigate if methylation regulates expression of DLEC1,
cancer cells were treated with 5-aza-20-deoxycytidine, a DNA
methyltransferase inhibitor. Freshly seeded cells were grown
overnight in normal medium, which was then replaced with
medium containing 1mM of 5-aza (Sigma-Aldrich Corporation,
MO, USA). Cells were allowed to grow for 72h, with 5-aza-
containing medium changed every 24h, and harvested for DNA
and RNA extraction. A cell viability of 470% was retained after
72h of treatment.
Methylation-specific PCR
Deleted in lung and oesophageal cancer 1 methylation status was
assessed by a fluorescence based real-time detection quantitative
methylation-specific PCR (MSP) with primers DLEC-m1, DLEC-m2
(Table 1) and a TaqMan
s probe 50-6FAM-TAATCAAACTTACGC
TCACTTCGTCGCCG-BHQ1-30 (Biosearch Technology, CA, USA)
(Weisenberger et al, 2006). A reference gene MYOD1 was
employed to normalise the DNA input of each sample as
previously described (Eads et al, 1999; Kohonen-Corish et al,
2007). Quantitative real-time PCR was performed for DLEC1 and
MYOD1 in parallel using the RealMasterMix Probe ROX (Eppen-
dorf, Hamburg, Germany) in the ABI7900HT Sequence Detection
System (Applied Biosystems, CA, USA). Deleted in lung and
oesophageal cancer 1 methylation was scored as present when the
value of (DLEC1/MYOD1 100%)X5 or absent if the value is o5.
All samples were run in duplicate.
Methylation-specific PCR of other chromosome 3p genes RARb,
MLH1, RASSF1A and BLU was carried out (Table 1) together with
MYOD1 amplification, as previously described (Eads et al, 1999;
Kohonen-Corish et al, 2007). PCR steps included 30s for
denaturing, annealing and extension (40 cycles), initial denatura-
tion and final elongation for 10min, and annealing temperatures of
551C( MLH1), 571C( MYOD1), 631C( BLU), and 581C( RARb,
RASSF1A).
Immunohistochemistry and MSI analysis
MLH1 expression on tissue microarrays was analysed as part of a
previous study (Cooper et al, 2008). Matched normal bronchial
mucosa or peripheral lung parenchyma specimens were used as
control tissue for each patient. MLH1 expression was scored
semiquantitatively by multiplying the percentage of cells showing
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Figure 1 (A) Schematic drawing of the short arm of chromosome 3 and
the relative location of the RARb, MLH1, DLEC1, RASSF1A and BLU genes.
(B) DLEC1 (NM_005106) and GAPDH expression using RT–PCR (two
upper panels) and methylation status using MSP (two bottom panels) in
lung cancer cell lines and in normal human lung tissue. (C) Restoration of
DLEC1 expression and concomitant demethylation of the CpG island in
H1299 cells using the 5-aza treatment.
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snuclear expression and the intensity of staining using a 3-tier
grading system (1¼weak, 2¼moderate and 3¼strong staining).
Reduced MLH1 expression was taken for a score less than 100, of
the maximum score of 300. MSI was analysed as previously
described (Kohonen-Corish et al, 2005, 2006), except that only two
markers BAT25 and BAT26 were evaluated, which are sufficient for
detecting high MSI (Suraweera et al, 2002).
Statistical and survival analysis
Correlation between DLEC1 methylation and clinicopathologic
parameters was determined using the w
2 test while survival analysis
was performed using the Kaplan–Meier log-rank and Cox
Proportional Hazards Model in the StatView package, and
Po0.05 was regarded as statistically significant. Only those
variables that were significant predictors of survival outcome in
univariate analysis were incorporated into multivariate analyses.
RESULTS
High correlation between promoter methylation and loss
of expression of DLEC1
Expression of DLEC1 was assessed by RT–PCR in five lung cancer
cell lines. While DLEC1 was expressed in normal lung tissue, no
expression was detected in the A427, A549 and H1299 lung cancer
cell lines (Figure 1B). We assessed DLEC1 methylation using
methylation-specific PCR (MSP). Only the methylated allele was
detected in the three cell lines where DLEC1 was not expressed,
while both the unmethylated and methylated alleles were detected
in cell lines expressing DLEC1 (Figure 1B). Methylation was rare in
normal lung tissue (2.5%, 200 specimens analysed). To determine
whether methylation directly regulates the silencing of DLEC1, the
cell line H1299 was treated with 5-aza, a DNA methyltransferase
inhibitor. After 3 days of 5-aza treatment, DLEC1 expression was
restored and demethylation observed (Figure 1C).
Promoter methylation of DLEC1, MLH1, RARb, RASSF1A
and BLU in lung cancer
We employed MSP to assess the promoter methylation status of
the five 3p candidate genes in 239 NSCLCs. Methylation was
detected in 123 patients (51.5%) for RARb, 86 (36.0%) for MLH1,
93 (38.9%) for DLEC1, 78 (32.6%) for RASSF1A and 85 (35.6%) for
BLU (Table 2). Next we investigated the relationship between
methylation of each set of two out of five genes. Significant
correlation was observed between DLEC1 and MLH1 (P¼0.0002),
DLEC1 and RASSF1A (P¼0.0003), and RASSF1A and BLU
methylation (P¼0.017). MLH1 methylation was also associated
with RASSF1A (P¼0.0006) and BLU (P¼0.0005) (Table 3).
Methylation of at least one of the five genes was detected in 204
of 239 (85.4%) patients; methylation of at least two genes in 139
(58.2%); three genes in 77 (32.2%); four genes in 36 (15.1%); and
methylation of all five genes was detected in only nine (3.8%)
patients.
MLH1 expression in lung cancer tissue and MSI
Expression of MLH1 was previously determined using immuno-
histochemistry on tissue microarrays in 105 of the 239 patients
(Cooper et al, 2008). MSI was analysed in the whole cohort of 239
patients. Reduced MLH1 expression was detected in seven of the
105 cancers including an apparent loss of MLH1 expression in two
cancers, but none of the matching DNA specimens prepared from
a larger area of the tumour showed any MSI using markers BAT25
and BAT26. Also, none of the seven cancers with reduced MLH1
expression showed MLH1 promoter methylation. In the rest of the
cohort MSI-H was detected in a stage 1B ADC (one marker) and a
stage 2A LCC (both markers), of which only the latter was
methylated in MLH1. There was no significant correlation between
reduced MLH1 expression and survival (P¼0.421).
Methylation of DLEC1 and MLH1 are associated with poor
patient survival
A statistically significant association between methylation and
histologic type was observed, where MLH1 methylation had a
higher frequency in SCC (45.6%) and LCC (40.7%) compared
with ADC (22.8%); RASSF1A methylation was associated with
LCC (53.7%); BLU and RARb methylation with ADC (45.7% and
60.9%). Furthermore, MLH1 and DLEC1 methylation were
associated with the presence of regional lymph-node metastases
and AJCC stage II. No association was observed between
methylation of the five genes and age of diagnosis, gender or
tumour differentiation status, except that BLU methylation was
more common in older patients (Table 2).
Methylation of DLEC1 (P¼0.0005), MLH1,( P¼0.004), and
RASSF1A (P¼0.024) as well as regional lymph node status
(Po0.0001) and AJCC stage (Po0.0001) were associated with
poorer overall survival (Figure 2 and Table 2). RARb and BLU
methylation were not prognostic in the whole NSCLC cohort using
the Kaplan–Meier log-rank analysis (P¼0.313 and 0.474).
Regional lymph node metastases and AJCC stage are two of the
known prognostic factors for NSCLC and these two parameters are
dependent predictors of survival in our cohort. Therefore, a
bivariate analysis with the molecular marker predictor (DLEC1,
MLH1 or RASSF1A methylation) and AJCC stage was set up.
Methylation of either DLEC1 or MLH1 but not RASSF1A was a
prognostic indicator independent of AJCC stage in the entire
patient cohort (Table 4). Deleted in lung and oesophageal cancer 1
methylation was also a prognostic factor independent of AJCC
stage in the SCC subgroup of patients (HR, 1.754; 95% CI, 1.023–
3.007; P¼0.041) and MLH1 methylation in LCC (HR, 2.926; 95%
CI, 1.358–6.308; P¼0.006).
Table 1 PCR primers used in the promoter methylation analysis of RARb, MLH1, DLEC1, RASSF1A and BLU
Gene Forward primer Reverse primer
RARb-m
a 50-TCGAGAACGCGAGCGATTC-30 50-GACCAATCCAACCGAAACGA-30
MLH1-m 50-AGCGATTTTTAACGCGTAAGC-30 50-CTCAATACCTCGTACTCACG-30
DLEC1-m 50-TTTCGTTGCGTATTTAAGATATTTC-30 50-CGTAACGCTCATTCTCGCTACC-30
DLEC1-u
b 50-TAGTTTTGTAGTTTGGTTTTGTT-30 50-ACAAAATATCTTAAATACACAACA-30
RASSF1A-m 50-TTAGCGAAGTACGGGTTTAATC-30 50-CTACCGTATAAAATTACACGCG-30
BLU-m 50-CGTGGGTTATAGTTCGAGAAAGC-30 50-AACGAATTAACCGCGCCTACGC-30
MYOD1
c 50-CCAACTCCAAATCCCCTCTCTAT-30 50-TGATTAATTTAGATTGGGTTTAGAGAAGGA-30
aPrimers specific for methylated, bisulphite converted DNA.
bPrimers specific for unmethylated, bisulphite converted DNA.
cControl primers not including CpG sites specific for
bisulphite converted DNA.
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affect patient prognosis (Figure 2; Table 4). Concordant MLH1/
DLEC1 methylation was associated with poorer overall survival in
both univariate (HR, 2.075; 95% CI, 1.428–3.015; P¼0.0001) and
bivariate (HR, 1.668; 95% CI, 1.138–2.447; P¼0.009) analyses.
Also, MLH1 methylation was prognostic in combination with
RASSF1A methylation independent of AJCC stage in all patients
(HR, 1.688, 95% CI, 1.127–2.529; P¼0.011) and particularly in the
LCC cohort (HR, 3.223; 95% CI, 1.482–7.008; P¼0.003).
DISCUSSION
Deleted in lung and oesophageal cancer 1 is a candidate tumour
suppressor gene in multiple cancers. Although the function of
DLEC1 is unclear, it suppresses tumour growth or reduces
invasiveness of cancer cells (Daigo et al, 1999; Kwong et al,
2006, 2007). In this study, we demonstrate for the first time that the
DLEC1 promoter is methylated in lung cancer. The demethylating
agent 5-aza reversed loss of mRNA expression in lung cancer cell
lines. Frequent DLEC1 methylation (34.2%) was observed in
NSCLC and was most common in SCC (47.8%). DLEC1 methyla-
tion was cancer-specific, as it was only rarely detected in matching
normal lung tissue, and was strongly associated with stage II
tumours and the spread of cancer to regional lymph nodes
(Po0.0001). DLEC1 methylation was also associated with shorter
overall survival in the whole cohort and in the SCC group of
patients, and this remained statistically significant upon bivariate
analysis with AJCC stage (Table 4). As there is no antibody
available for DLEC1, we could not determine what proportion of
methylated tumours would show loss or reduced DLEC1 protein
expression. However, it has been previously demonstrated that
DLEC1 RNA expression was lost in eight of 30 primary lung
cancers and that this was not due to gene mutations (Daigo et al,
1999).
The MLH1 gene is located within 1Mb of DLEC1 in a locus that
shows 55% LOH in NSCLC (Benachenhou et al, 1998). Therefore,
there has been some interest in determining the biological
significance of reduced MLH1 gene expression and promoter
methylation in lung cancer. As gene alterations can cause either
increased sensitivity or resistance of tumours to chemotherapy
treatment, we excluded those patients who had received induction
chemotherapy prior to surgery to avoid a possible bias in the
molecular analyses. MLH1 methylation was found in 36% of the
cancers but did not result in the loss of gene expression in the 105
cancers analysed with immunohistochemistry. Only 6.7% of the
cancers showed reduced MLH1 expression with stringent criteria
Table 2 Association of clinicopathologic variables with poor overall survival and with RARb, MLH1, DLEC1, RASSF1A and BLU promoter methylation in the
cohort of 239 NSCLC patients.
Kaplan–
Meier
log-rank RARb methylation hMLH1 methylation DLEC1 methylation RASSF1A methylation BLU methylation
No. of patients No. of patients No. of patients No. of patients No. of patients
Clinicopathologic
parameters P-value +
a  
b P-value +   P-value +   P-value +   P-value +   P-value
Age 0.5754
o68 (n¼117) 63 54 0.4706 39 78 0.4032 49 68 0.3567 41 76 0.4371 34 83 0.0397
468 (n¼122) 60 62 47 75 44 78 37 85 51 71
Gender 0.1680
Male (n¼155) 76 79 0.3068 57 98 0.7293 61 94 0.8488 49 106 0.6468 53 102 0.5475
Female (n¼84) 47 37 29 55 32 52 29 55 32 52
Tumour differentiation 0.2864
Poor (n¼103) 48 55 0.3388 44 59 0.3106 44 59 0.7712 35 68 0.3738 34 69 0.2847
Moderate (n¼113) 65 48 35 78 41 72 37 76 41 72
Well (n¼20) 9 11 6 14 7 13 4 16 10 10
Unknown (n¼3) 1 2 1 2 1 2 2 1 0 3
Histologic type 0.5207
ADC (n¼92) 56 36 0.0317 21 71 0.0047 29 63 0.0696 25 67 0.0008 42 50 0.0278
LCC (n¼54) 20 34 22 32 19 35 29 25 17 37
SCC (n¼92) 47 45 42 50 44 48 23 69 25 67
Primary tumour stage 0.1014
T1 (n¼64) 31 33 0.8517 16 48 0.0995 17 47 0.0555 19 45 0.8406 22 42 0.7303
T2 (n¼154) 81 73 62 92 66 88 52 102 57 97
T3 (n¼21) 11 10 8 13 10 11 7 14 6 15
Regional lymph node status o0.0001
N0 (n¼174) 91 83 0.6728 54 120 0.0091 53 121 o0.0001 52 122 0.1378 68 106 0.0632
N1 (n¼65) 32 33 32 33 40 25 26 39 17 48
AJCC staging o0.0001
Stage I (n¼153) 80 73 0.7341 46 107 0.0110 43 110 o0.0001 45 108 0.1562 62 91 0.0327
Stage II (n¼86) 43 43 40 46 50 36 33 53 23 63
Total 123 116 86 153 93 146 78 161 85 154
a+Indicates number of patients with a methylated tumour.
b Indicates number of patients with no methylation detected.
Table 3 P-values for pairwise correlation of promoter methylation in the
3p genes
MLH1 DLEC1 RASSF1A BLU
P-value P-value P-value P-value
RARb 0.0691 0.1032 0.5543 0.7343
MLH1 — 0.0002 0.0006 0.0005
DLEC1 — — 0.0003 0.0550
RASSF1A — — — 0.0173
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s(o100 of the maximum score of 300) and none of these specimens
were methylated. We also found that MLH1 methylation was
patchy and/or monoallelic in region C of the MLH1 promoter by
using combined bisulphite-restriction analysis (COBRA, Hitchins
et al, 2007) (data not shown). This is consistent with the finding
that MSI is extremely rare in NSCLC.
It is intriguing therefore, that MLH1 methylation showed strong
prognostic significance, which is reported here for the first time. It
was a marker of poor survival in the whole cohort, and particularly
in the LCC subgroup, with both univariate and bivariate analyses.
This is in contrast to colorectal adenocarcinoma where MLH1
methylation causes the MSI-H phenotype, which has improved
prognosis. There was a high correlation between DLEC1 and MLH1
methylation (P¼0.0002). As for DLEC1, MLH1 methylation was
associated with stage II tumours and spread to regional lymph
nodes. Concordant methylation of MLH1 and DLEC1 was also a
marker of poor prognosis independent of stage in the whole cohort
(Table 4).
The close correlation between MLH1 and DLEC1 methylation
may be a consequence or a byproduct of a long-range epigenetic
effect in this region of chromosome 3p. The first such
chromosomal region reported was 2q14.2, which shows modifica-
tion of chromatin structure such as histone H3-K9 methylation
in colon cancer cells. This results in clusters of both methylated
and unmethylated genes being coordinately suppressed (Frigola
et al, 2006). It has recently been shown that DLEC1 and MLH1 are
also subject to long-range epigenetic regulation in colon cancer
(Hitchins et al, 2007). Multiple genes in this region can be
simultaneously silenced through promoter hypermethylation and
histone methylation in MSI-positive colorectal cancers. This effect
appears to extend centromeric from the MLH1 gene and does not
always reach DLEC1 in all specimens. In bladder cancer there is
also evidence of such long-range epigenetic regulation around the
DLEC1 gene, but here the predominant mechanism is gene
silencing through histone methylation rather than CpG methyla-
tion, and MLH1 was not analysed (Stransky et al, 2006). The two
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Figure 2 Kaplan–Meier log-rank analysis of overall survival of NSCLC patients stratified by promoter methylation of (A) DLEC1;( B) MLH1,( C) RASSF1A,
(D) RARb,( E) BLU,( F) DLEC1/MLH1,( G) MLH1/RASSF1A and (H) DLEC1/RASSF1A (*Po0.05; **Po0.005; ***Po0.0001).
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neighbour PLCD1, are silenced through DNA methylation and H3-
K9 dimethylation in colorectal cancer whereas in bladder cancer they
are silenced through histone H3-K9 trimethylation. This suggests
that there are tissue-specific differences in this regulation. Therefore,
if such long-range epigenetic regulation of chromosome 3p is also
operating in lung cancer, it is possible that some genes in the region
may be affected less than others. As a consequence the overall
methylation in this region could serve as a marker of poorer
prognosis but only some genes show complete loss of function.
The other three genes analysed in this study RASSF1A, BLU and
RARb are known to be methylated in lung cancer and all have
shown functional characteristics of tumour suppressor genes
(Toulouse et al, 2000; Shivakumar et al, 2002; Agathanggelou
et al, 2003). RARb is located 12Mb telomeric from MLH1, and
RASSF1A and BLU about 12Mb centromeric from DLEC1. RASSF1
methylation was also highly correlated with DLEC1 (P¼0.0003)
and MLH1 methylation (P¼0.0006), whereas RARb was methy-
lated independent of the other genes. The correlation between
RASSF1A and BLU methylation observed here (P¼0.017) has also
been described previously (Agathanggelou et al, 2003). However,
none of these three markers were as strongly prognostic as DLEC1
and MLH1 methylation in this cohort. In a previous study
RASSF1A methylation correlated with poor survival (Tomizawa
et al, 2002), but this has not been confirmed in all cohorts
(Toyooka et al, 2004; Choi et al, 2005). Here, RASSF1A methylation
was a prognostic marker in univariate analyses but not indepen-
dent of stage, as was also observed previously (Choi et al, 2005). It
was interesting that concordant methylation of MLH1 with RASSF1
was an independent marker of poor prognosis. This suggests that a
possible long-range epigenetic effect may extend centromeric from
the DLEC1 locus but not telomeric from the MLH1 locus.
Taken together, our study has described two new prognostic
markers, methylation of DLEC1 and MLH1 on chromosome 3p.
Methylation of these two genes is clearly associated with each other
and with methylation of RASSF1 and BLU, which are B12Mb
centromeric from DLEC1. MLH1 methylation itself does not lead to
gene silencing in lung cancer and the biological significance of
DLEC1 methylation also needs further study. In any case,
concordant methylation of MLH1 with DLEC1 or RASSF1A is a
valuable prognostic indicator in lung cancer. Future studies should
reveal whether DLEC1, another gene or perhaps multiple genes
in this region are functionally the most important in lung
carcinogenesis.
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Table 4 Association of gene promoter methylation with survival in a univariate and a bivariate analysis, which takes into account AJCC stage of cancer
Cox Proportional Regression Model
Univariate Bivariate Univariate Bivariate Univariate Bivariate Univariate Bivariate
Clinical or molecular
marker All samples (No.¼239) ADC (No.¼92) LCC (No.¼54) SCC (No.¼92)
AJCC stage
HR 2.795 2.580–2.728 3.126 2.767–3.042 2.930 2.438–3.256 2.594 2.411–2.597
95% CI 2.009–3.889 1.808–5.404 1.417–6.056 1.506–4.467
P o0.0001 o0.0001 o0.0001 o0.0007 0.004 o0.021 0.0006 o0.002
MLH1/DLEC1
HR 2.075 1.668 2.347 1.415 2.146 2.284 1.731 1.525
95% CI 1.428–3.015 1.138–2.447 1.210–4.555 0.683–2.932 0.939–4.906 0.992–5.257 0.984–3.043 0.863–2.696
P 0.0001 0.009 0.012 0.350 0.070 0.052 0.057 0.146
MLH1/RASSF1A
HR 1.951 1.688 1.702 1.245 3.011 3.223 1.390 1.206
95% CI 1.307–2.913 1.127–2.529 0.832–3.483 0.595–2.607 1.395–6.501 1.482–7.008 0.677–2.854 0.586–2.482
P 0.001 0.011 0.146 0.561 0.005 0.003 0.370 0.611
DLEC1/RASSF1A
HR 1.505 1.137 1.763 1.102 1.292 0.925 1.338 1.213
95% CI 1.015–2.233 0.759–1.705 0.927–3.352 0.548–2.214 0.574–2.909 0.395–2.163 0.686–2.607 0.623–2.362
P 0.042 0.533 0.084 0.785 0.536 0.857 0.393 0.571
MLH1
HR 1.621 1.421 2.034 1.512 2.591 2.926 1.007 0.972
95% CI 1.164–2.257 1.016–1.988 1.171–3.535 0.842–2.714 1.220–5.499 1.358–6.308 0.597–1.697 0.576–1.640
P 0.004 0.040 0.012 0.166 0.013 0.006 0.980 0.915
DLEC1
HR 1.783 1.471 1.681 1.337 1.454 1.103 1.968 1.754
95% CI 1.283–2.479 1.050–2.062 0.983–2.872 0.766–2.333 0.698–3.029 0.514–2.366 1.155–3.353 1.023–3.007
P 0.0006 0.025 0.058 0.306 0.317 0.802 0.013 0.041
RASSF1A
HR 1.474 1.259 1.397 1.174 2.453 1.902 1.138 1.021
95% CI 1.049–2.071 0.892–1.776 0.796–2.451 0.661–2.084 1.133–5.310 0.856–4.230 0.620–2.089 0.556–1.876
P 0.025 0.190 0.244 0.584 0.023 0.115 0.676 0.947
Abbreviations: AJCC¼American Joint Committee on Cancer; HR¼Hazard Ratio; CI¼confidence interval.
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